Akeso, Inc.
9926.HK · HKSE
Market closed88.35-13.45 (-13.21%)
Key statistics
Previous close101.80
Open99.70
Day high100.10
Day low88.10
52-week high179.00
52-week low80.20
Market cap81.28B
Volume23.63M
Average volume13.71M
P/E ratio-65.86
Forward P/E—
EPS-1.34
Dividend yield0.00%
Market context
Why it moved
9926.HK (Akeso, Inc.) suffered a sharp decline as Hong Kong biotech stocks experienced a broad sector-wide selloff, with sentiment-driven weakness hitting the space hard amid a broader rotation away from AI and biotech-related themes in the Hong Kong market.
What is happening
Recent company-specific developments and publisher coverage.
BioWorld News · July 18, 2026Akeso sets durability bar as immuno-oncology 2.0 race heats upFierce Pharma · June 18, 2026ASCO: Akeso’s ivonescimab bests PD-1 inhibitor in lung cancer chemo combos, slashing death risk by 34%The Clinical Trial Vanguard · June 18, 2026Akeso’s Ivonescimab OS Data From HARMONi-6 Selected for ASCO PlenaryBloomberg.com · June 1, 2026Watch Akeso To Boost Manufacturing Of Cancer DrugBioPharma Dive · May 31, 2026Akeso, Summit drug extends survival in closely watched lung cancer trialSTAT · May 31, 2026Akeso and Summit’s ivonescimab extends survival in squamous cell lung cancerSimply Wall Street · March 26, 2026Akeso Advances Next Generation Oncology Pipeline With New Trial ClearancesPR Newswire · March 4, 2026INOVIO and Akeso Announce Clinical Collaboration to Advance Novel Combination Therapy for Glioblastoma (GBM) Mt Newswire · June 11, 2026Akeso's Trustee, Senior Management to Buy Back Shares Mt Newswire · June 11, 2026Akeso Board Approves HK$200 Million Share Purchase Plan Mt Newswire · June 1, 2026Nomura Adjusts Akeso's Price Target to HK$142.50 From HK$142.75, Keeps at Buy Mt Newswire · April 23, 2026Nomura Adjusts Akeso's Price Target to HK$142.75 From HK$112.73, Keeps at Neutral Mt Newswire · March 27, 2026Akeso Widens Loss in 2025; Shares Climb 3% Mt Newswire · March 5, 2026Nomura Adjusts Akeso's Price Target to HK$112.73 From HK$120.64, Keeps at Neutral Mt Newswire · February 3, 2026Akeso Grants Commercialization Rights for Hypercholesterolemia Drug to Hubei Jumpcan Pharmaceutical Unit Mt Newswire · October 21, 2025Akeso's Ivonescimab Shows Strong Phase 3 Results in Lung Cancer Trial